Matica Biotechnology, Inc. Announces Master Research Agreement with Texas A&M
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a master research agreement with the Center for Innovation in Advanced Development and Manufacturing (CIADM) at Texas A&M University Health Science Center (TAMHSC). The agreement covers joint research and development projects for plasmid, protein and viral vector products in compliance with FDA regulations.
“Texas A&M University is internationally renowned for its research programs developing novel vaccines and therapies to improve public health,” stated Dr. Byung Se So, CEO of Matica Bio. “Matica Bio is excited to partner with the TAMHSC CIADM staff as we strive to innovate manufacturing solutions for our clients’ novel cell and gene therapy products. With GMP operations and laboratories of both organizations co-located in College Station, working together seemed like a natural fit to fully realize our clients’ success.”
Dr. William Jay Treat, Principle Investigator for the CIADM at TAMHSC noted, “The CIADM’s objectives include facilitating rapid R&D and promoting novel product development of vaccines and therapies. Matica Bio’s clients are at the forefront of advanced therapy development, and we welcome the opportunity to collaborate through research studies to bring these potentially lifesaving medicines to patients.”
Utilizing platform technologies and systems designed for the rapid transfer of production processes from pilot development into GMP manufacturing, Matica Bio is addressing its clients’ acute need for fast, reliable and innovative scale-up of viral vector manufacture to keep pace with the accelerated clinical development timeframes often associated with many breakthrough therapies.
Matica Bio’s Texas facility is scheduled to open in Q3 2021 utilizing a bioreactor-based platform for the production of Lentivirus and AAV vectors. Matica Bio’s development and operations staff average over 10 years in the viral vector CDMO industry, bringing a wealth of knowledge and operational experience together to drive its clients’ product development success.